Catalent, Inc. (CTLT)
| Previous close | 55.80 |
| Open | 55.88 |
| Bid | 55.85 x 800 |
| Ask | 55.86 x 1200 |
| Day's range | 55.76 - 56.04 |
| 52-week range | 31.45 - 60.20 |
| Volume | |
| Avg. volume | 2,743,158 |
| Market cap | 10.109B |
| Beta (5Y monthly) | 1.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment
SOMERSET, N.J., March 07, 2024--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, has today published its fiscal 2023 Corporate Responsibility Report, highlighting positive progress across every pillar of Catalent’s corporate responsibility strategy – People, Environment, and Community. The report also outlines the company’s future commitments as it progresses its mission to help people lead better and healthier lives.
- Business Wire
Catalent, Inc. Reports Second Quarter Fiscal 2024 Results
SOMERSET, N.J., February 09, 2024--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the second quarter of fiscal 2024, which ended December 31, 2023.
- Business Wire
Novo Holdings to Acquire Catalent
COPENHAGEN, Denmark & SOMERSET, N.J., February 05, 2024--Catalent, Inc. (NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, today announced that they have entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an
